
Stille Q2 2025 - Temporary weakness, expected rebound in H2

Redeye updates its forecasts and fair value range for Stille following the Q2 report and the acquisition of UK-based Surgical Holdings. The company has faced headwinds in H1 but is now positioned for a rebound in H2, currently trading at around 13x 2025e EV/EBITDA.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Stille Q2 2025 - Temporary weakness, expected rebound in H2